Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review
Endocrinology, Diabetes & Metabolism · 2024-01 · 7 (1)
DOI: 10.1002/edm2.464 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 20.12.2023. Verfasst von Gabrielle Page-Wilson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Cushing Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objective
The objective of this systematic literature review (SLR) was to summarize the latest studies evaluating the burden of illness in endogenous Cushing's syndrome (CS), including the impact of CS on overall and domain‐specific health‐related quality of life (HRQoL) and the economic burden of CS to provide a holistic understanding of disease and treatment burden.
Methods
An SLR was conducted in PubMed, MEDLINE and Embase using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) checklist to identify peer‐reviewed manuscripts and conference abstracts published in English from 2015 to December 4, 2020.
Results
Forty‐five publications were eligible for inclusion; data were extracted from 37 primary studies while 8 SLRs were included for reference only. Thirty‐one studies reported HRQoL using validated patient reported outcome (PRO) measures in pre‐ or post‐surgery, radiotherapy and pharmacotherapy patients. Overall, this SLR found that patients with CS have worse outcomes relative to healthy populations across specific dimensions, such as depression, despite an improvement in HRQoL post‐treatment. These findings reveal that CS symptoms are not fully resolved by the existing care paradigm. Few studies report on the economic burden of CS and currently available data indicate a high direct healthcare system cost burden.
Conclusions
Patients with CS experience a significant, complex and multifactorial HRQoL burden. Symptom‐specific burden studies are sparse in the literature and the understanding of long‐term CS symptomatic burden and economic burden is limited. This review intends to provide an updated reference for clinicians, payers and other stakeholders on the burden of CS as reported in published literature and to encourage further research in this area.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Columbia University Irving Medical Center, New York, New York, USA.
- Trinity Life Sciences, Waltham, Massachusetts, USA.
- Formerly at Strongbridge Biopharma plc, a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., Trevose, Pennsylvania, USA.
- Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Eliza B Geer
Förderung
- NCI NIH HHS
Zitieren
APA
Page-Wilson, G., Oak, B., Silber, A., Okeyo, J. C., Ortiz, N., O'Hara, M., Moloney, S., & Geer, E. B. (2024). Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review. Endocrinology, Diabetes & Metabolism, 7(1). https://doi.org/10.1002/edm2.464
Vancouver
Page-Wilson G, Oak B, Silber A, Okeyo JC, Ortiz N, O'Hara M, et al. Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review. Endocrinology, Diabetes & Metabolism. 2024;7(1). doi:10.1002/edm2.464
BibTeX
@article{PageWilson2024,
author = {Page-Wilson, Gabrielle and Oak, Bhagyashree and Silber, Abigail and Okeyo, Janetricks C and Ortiz, Nancy and O'Hara, Matthew and Moloney, Stephen and Geer, Eliza B},
title = {Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
volume = {7},
number = {1},
doi = {10.1002/edm2.464}
}
EUVIMED